On March 12, the State Drug Administration held a party group (enlarged) meeting to convey and study the important speech of General Secretary Xi Jinping during the National People’s Congress and the spirit of the National People’s Congress, and to study and deploy the implementation measures. Li Li, secretary of the party group and director of the State Drug Administration, presided over the meeting and delivered a speech, while Xu Jinghe, Zhao Junning, Huang Guo, and Lei Ping, members of the party group and deputy directors of the Bureau, director of the Bureau of Drug Safety, and the comrades in charge of the Discipline Inspection Group of the State Supervision Committee of the Central Commission for Discipline Inspection and Supervision of the State Supervision Committee of the State Council in the General Administration of Market Supervision attended the meeting.
The meeting considered that the National People’s Congress and the National People’s Congress were important meetings held in the 75th anniversary of the founding of New China and the crucial year of realizing the goals and tasks of the 14th Five-Year Plan. General Secretary Xi Jinping delivered a series of important speeches during the two sessions of the National People’s Congress, making important remarks on the development of new productive forces, comprehensively deepening reforms, promoting scientific and technological innovation, strengthening ecological protection, etc., which have strong political mobilization, ideological leadership, spiritual inspiration and practical guidance. To study and implement the spirit of General Secretary Xi Jinping’s important speech and the full implementation of General Secretary Xi Jinping’s important instructions on drug supervision work is closely integrated, so that one study, one implementation, one implementation, to take practical action to firmly support the “two established”, resolutely achieve “two Maintenance”.
The meeting pointed out that the government work report on the strict supervision of drug safety, accelerate the development of innovative drugs, biomanufacturing, life sciences, to promote health insurance, medical, pharmaceutical synergistic development and governance, to expand the primary health care institutions of chronic diseases, common diseases, drug types, and to strengthen the protection of drugs for rare diseases and other series of deployments, which fully reflects the CPC Central Committee and the State Council of the high importance attached to the supervision of drugs and pharmaceutical innovation. Drug regulatory authorities should seriously grasp the refinement, implementation, supervision, strong and orderly promotion of the implementation of the work. To seriously do a good job in handling the recommendations and proposals, and effectively let the representatives and members of the insights into the improvement of the work of the specific policies and measures.
The meeting emphasized that we should seriously benchmark and refine the implementation of General Secretary Xi Jinping’s important speeches and the spirit of the National People’s Congress, to ensure that all decisions and deployments in the drug regulatory system to achieve results. First, we must protect the quality and safety of drugs as the most fundamental responsibility, to implement drug safety consolidation and enhancement of action as a grasp, stable and orderly disposal of risks and hidden dangers, improve the long-term mechanism of risk prevention and control, all-round building a solid drug safety bottom line. Second, we should study and plan to further deepen the drug regulatory reform policies and measures, provide efficient front-end guidance services for pharmaceutical innovation, actively promote the research and development of innovative drugs, high-end medical equipment and other listed, accelerate the cultivation and development of pharmaceutical new quality productivity. Third, to comprehensively strengthen the drug regulatory system and regulatory capacity building, and constantly strengthen the system innovation and means of innovation, accelerate the development of intelligent drug regulation and regulatory science, to provide strong support for safety and development.
The meeting requested that the drug regulatory cadres and workers should adhere to the diligence and integrity, and further enhance the sense of responsibility, “always assured that”, and effectively transformed into “everything in mind” of the power of action. To revitalize the spirit, the spirit of the central and departmental practice closely integrated, find the direction of force, planning work grasp, enhance the sense of service, and actively respond to the reasonable demands of the masses and enterprises. To do new work, break down the tasks one by one, refine the requirements, clear time frame, to ensure that the decisions and deployments are truly implemented into action, implemented into the work, reflected in the results. To clean the bottom line, strengthen the cadres all-round management and regular supervision, continue to rectify corruption in the field of medicine, seriously investigate and deal with the use of power for personal gain and other behaviors, and coordinate to grasp the quality and safety of medicines and the integrity of the supervisory team security “two security”.
State Drug Administration organs of the departments and bureaus and directly under the Beijing unit of the main responsible comrades to participate in the meeting.
Hongguan care about your health.
See more Hongguan Product→https://www.hgcmedical.com/products/
If there are any needs of medical comsumables, please feel free to contact us.
hongguanmedical@outlook.com
Post time: Mar-14-2024